Treatment of hyperparathyroidism and related disorders, such as hypercalcemia (reduction of PTH secretion through modulation of calcium ion receptors on parathyroid cells)
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
H05 CALCIUM HOMEOSTASIS
H05B ANTI-PARATHYROID AGENTS
H05BX Other anti-parathyroid agents
H05BX01 Cinacalcet
D03505 Cinacalcet hydrochloride (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Metabolic Bone Disease Agents
Calcium-sensing Receptor Agonist
Cinacalcet
D03505 Cinacalcet hydrochloride (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D03505 Cinacalcet hydrochloride (JAN/USAN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00513 Cinacalcet
D03505 Cinacalcet hydrochloride
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG00513 Cinacalcet
D03505 Cinacalcet hydrochloride
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Metabotropic glutamate receptor family
Calcium-sensing
CASR
D03505 Cinacalcet hydrochloride (JAN/USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03505
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03505
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03505
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03505
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D03505
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00513 Cinacalcet
Metabolizing enzyme inhibitor
DG01645 CYP2D6 inhibitor
DG00513 Cinacalcet